Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
NCT01254279
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
984
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostate Cancer Metastatic
Interventions
DRUG:
CABAZITAXEL
Sponsor
Sanofi